Ophthalmic surgical device manufacturer Nova Eye Medical has reported a record combination of sales growth and operating result improvement during the year ended 30 June 2024. Underpinned by solid performance in its core glaucoma segment including its flagship product, iTrack Advance, the company’s sales in July 2024 were materially above the previous year. Investments recently…
Medical device manufacturer Nova Eye Medical has reported strong sales growth of its glaucoma surgical devices for the year ended 30 June 2024. Revenue for the year ended 30 June 2024, mainly for sales of its ITrack Advance glaucoma surgical device, is expected to be $23.5 million (US$15.3 million), up 37 percent on the previous…
Ophthalmic treatment device manufacturer Nova Eye Medical has reported strong sales results following the US launch of its latest iTrack Advance glaucoma surgical device. The iTrack Advance is a consumable device with an illuminated fibre optic tip designed to improve the efficacy of canaloplasty surgery in treating glaucoma. The updated device was launched in May…
Ophthalmic treatment device manufacturer Nova Eye Medical has defined with the US Food and Drug Administration the clinical studies needed to progress to market its novel treatment for macular degeneration, a disease affecting the retina for which there is no cure. The company has been developing a 2RT minimally invasive retinal rejuvenation laser for intermediate…
Ophthalmic treatment device manufacturer Nova Eye Medical has reported strong sales for its glaucoma surgical device business in the four months to 31 October. The company sold iTrack and Molteno3 devices worth $4.4 million, up from $2.6 million in the four months to 30 June when sales were affected by Covid-19 lockdowns. iTrack is a…
Ophthalmic treatment device manufacturer Nova Eye Medical has established a new subsidiary, AlphaRET, to commercialise its laser technology for the treatment of intermediate age-related macular degeneration (iAMD). The new company will be the focus for developing the company’s 2RT minimally invasive nano-pulse ophthalmic laser therapy, and delineates the project from the company’s core business centred…
Newly renamed medical device manufacturer Nova Eye Medical has wasted no time expanding its product portfolio in the glaucoma field following the sale of its ophthalmic laser and ultrasound businesses. Nova, known before the sale this week as Ellex Medical Lasers, has used some of the $97.4 million proceeds to purchase the Molteno3 glaucoma drainage…
Ellex Medical Lasers will be reborn with the new name of Nova Eye Medical and will develop new opthalmic treatments following the completion of the sale of its opthalmic laser (pictured) and ultrasound businesses. The company told investors it had completed the sale of the businesses, together with the Ellex name, to London’s Lumibird Group…
In a bold move to capture a significant share of the global nerve repair market, Orthocell, a pioneer in regenerative medicine, has submitted a regulatory application to Health Canada for its leading product, Remplir. This step marks a strategic expansion into the Canadian market, valued at approximately US$75 million, with approvals anticipated in the latter…
Medical technology company Nova Eye Medical has seen sales including its new iTrack Advance glaucoma surgical device product of $5.7 million in the four months to 31 October, materially exceeding its forecast of $5.1 million. Launched in Europe and Canada in June, the iTrack Advance is a consumable device with an illuminated fibre optic tip…
